IL282231B2 - Deuterium-containing compounds - Google Patents

Deuterium-containing compounds

Info

Publication number
IL282231B2
IL282231B2 IL282231A IL28223121A IL282231B2 IL 282231 B2 IL282231 B2 IL 282231B2 IL 282231 A IL282231 A IL 282231A IL 28223121 A IL28223121 A IL 28223121A IL 282231 B2 IL282231 B2 IL 282231B2
Authority
IL
Israel
Prior art keywords
melflufen
deuterium
mol
compound
iii
Prior art date
Application number
IL282231A
Other languages
English (en)
Hebrew (he)
Other versions
IL282231A (en
IL282231B1 (en
Original Assignee
Oncopeptides Ab
Oncopeptides Innovation Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1816998.7A external-priority patent/GB201816998D0/en
Priority claimed from GBGB1909695.7A external-priority patent/GB201909695D0/en
Application filed by Oncopeptides Ab, Oncopeptides Innovation Ab filed Critical Oncopeptides Ab
Publication of IL282231A publication Critical patent/IL282231A/en
Publication of IL282231B1 publication Critical patent/IL282231B1/en
Publication of IL282231B2 publication Critical patent/IL282231B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL282231A 2018-10-18 2019-10-17 Deuterium-containing compounds IL282231B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1816998.7A GB201816998D0 (en) 2018-10-18 2018-10-18 Compounds
GBGB1909695.7A GB201909695D0 (en) 2019-07-05 2019-07-05 Compounds
PCT/EP2019/078250 WO2020079165A1 (en) 2018-10-18 2019-10-17 Compounds containing deuterium

Publications (3)

Publication Number Publication Date
IL282231A IL282231A (en) 2021-05-31
IL282231B1 IL282231B1 (en) 2025-03-01
IL282231B2 true IL282231B2 (en) 2025-07-01

Family

ID=68290247

Family Applications (1)

Application Number Title Priority Date Filing Date
IL282231A IL282231B2 (en) 2018-10-18 2019-10-17 Deuterium-containing compounds

Country Status (19)

Country Link
US (2) US12152087B2 (https=)
EP (1) EP3866931B1 (https=)
JP (2) JP7603199B2 (https=)
KR (1) KR102848971B1 (https=)
CN (1) CN112930214B (https=)
AU (1) AU2019362389B2 (https=)
BR (1) BR112021007060A2 (https=)
CA (1) CA3116198A1 (https=)
DK (1) DK3866931T3 (https=)
ES (1) ES2942468T3 (https=)
FI (1) FI3866931T3 (https=)
HU (1) HUE061801T2 (https=)
IL (1) IL282231B2 (https=)
MA (1) MA53904A (https=)
MX (1) MX2021004474A (https=)
PL (1) PL3866931T3 (https=)
SG (1) SG11202103726RA (https=)
WO (1) WO2020079165A1 (https=)
ZA (1) ZA202102492B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
EP4347615B1 (en) * 2021-06-01 2025-05-21 Synthon B.V. Process for making melflufen or a salt thereof
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
WO2023281007A1 (en) 2021-07-08 2023-01-12 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations
WO2026057823A1 (en) * 2024-09-13 2026-03-19 Oncopeptides Ab Bis-chloroethylamino derivatives for treating leukemia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012146625A1 (en) * 2011-04-28 2012-11-01 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
WO2014065751A1 (en) * 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
EA202091397A1 (ru) 2013-01-31 2020-09-04 Ауспекс Фармацетикалс, Инк. Бензохинолоновые ингибиторы vmat2
KR20150115807A (ko) * 2013-02-05 2015-10-14 임파 악치엔게젤샤프트 위치-특이적 비대칭 중수소 풍부 카테콜아민 유도체 및 상기 화합물을 포함하는 약제
EA201791466A1 (ru) 2013-12-03 2017-11-30 Оспекс Фармасьютикалз, Инк. Способы получения соединений бензохинолина
CN110229159B (zh) * 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
HRP20221106T1 (hr) 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
GB201507903D0 (en) * 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012146625A1 (en) * 2011-04-28 2012-11-01 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
WO2014065751A1 (en) * 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide

Also Published As

Publication number Publication date
US20210388024A1 (en) 2021-12-16
ZA202102492B (en) 2024-04-24
JP2022512736A (ja) 2022-02-07
US20250115637A1 (en) 2025-04-10
JP2024150488A (ja) 2024-10-23
DK3866931T3 (da) 2023-04-24
IL282231A (en) 2021-05-31
KR20210078487A (ko) 2021-06-28
PL3866931T3 (pl) 2023-06-19
WO2020079165A1 (en) 2020-04-23
ES2942468T3 (es) 2023-06-01
AU2019362389B2 (en) 2024-12-12
KR102848971B1 (ko) 2025-08-21
EP3866931B1 (en) 2023-02-15
MA53904A (fr) 2021-08-25
CA3116198A1 (en) 2020-04-23
SG11202103726RA (en) 2021-05-28
BR112021007060A2 (pt) 2021-07-20
FI3866931T3 (fi) 2023-05-10
HUE061801T2 (hu) 2023-08-28
CN112930214A (zh) 2021-06-08
CN112930214B (zh) 2025-05-16
EP3866931A1 (en) 2021-08-25
US12152087B2 (en) 2024-11-26
IL282231B1 (en) 2025-03-01
JP7603199B2 (ja) 2024-12-20
MX2021004474A (es) 2021-08-24
AU2019362389A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
US20250115637A1 (en) Compounds containing deuterium
JP5043433B2 (ja) プロスタサイクリン類似体の送達のための化合物及び方法
KR101976218B1 (ko) 4-히드록시부티르산 중수소화 유사체
KR101125932B1 (ko) (3s)-3-[n-(n'-(2-tert-부틸페닐)옥사밀)알라니닐]아미노-5-(2',3',5',6'-테트라플루오로페녹시)-4-옥소펜탄산의 결정 형태
KR102762016B1 (ko) 니트록솔린 전구약물 및 이의 용도
TW201331177A (zh) 治療活性組合物及其使用方法
AU2020259142A1 (en) Novel formulations comprising melflufen
HK40048606B (en) Compounds containing deuterium
HK40048606A (en) Compounds containing deuterium
EA045396B1 (ru) Соединения, содержащие дейтерий
JPH05105627A (ja) 腸機能性疾患の治療に用いられる新規な医薬組成物と、その調整方法と、治療用医薬の調製方法
WO2026024591A1 (en) Tryptamine prodrug solid forms
EP3081556A1 (en) Amide compound and pharmaceutical comprising same
HK40047998A (en) Nitroxoline prodrug and use thereof
WO2024120448A1 (zh) 一种hdac抑制剂及其用途
WO2021257669A1 (en) Synthesis of substituted arylmethylureas, analogues, and crystalline forms thereof and methods of using same
WO2020046941A1 (en) Crystalline forms of substituted dihydroindene-4-carboxamide compounds and methods of preparing and using same